Furthermore, in breast cancer diagnostics, only a limited number of serum-based biomarkers have received FDA approval for monitoring advanced or recurrent cases, namely MUC-1 (CA27.29 and CA15-3) and carcinoembryonic antigen (CEA) [178,179]. This evidence concerns the gene CEACAM5 and breast cancer.